DAIC

APRIL 9, 2024

reduction in low-density lipoprotein (LDL) cholesterol, on average, six months after starting treatment. Nissen, MD , chief academic officer in the Heart, Vascular, and Thoracic Institute at Cleveland Clinic and the study’s lead author. of cases at baseline and at the final treatment phase assessment, respectively.

Cholesterol 52

Cholesterol Blood Pressure Heart Disease Research 52

Journal of the American Heart Association

DECEMBER 19, 2024

BackgroundElevated lowdensity lipoprotein cholesterol is a risk factor for atherosclerotic cardiovascular disease, including acute ischemic stroke (AIS), due to large and smallvessel disease. Cholesterol management guidelines recommend lipidlowering therapy (LLT) to prevent atherosclerotic cardiovascular disease events.

Stroke 40

Stroke Strokes Cholesterol Cardiovascular Disease 40

Journal of the American Heart Association

JANUARY 16, 2024

Key secondary and exploratory outcomes include improvement in a composite cardiovascular health metric, CR engagement, quality of life, health factors (including low‐density lipoprotein‐cholesterol, hemoglobin A1c, weight, diet, smoking cessation, blood pressure), and psychosocial factors.

Coronary Artery Bypass Graft 40

Coronary Artery Bypass Graft Technology Cardiac Rehabilitation Quality of Life 40

DAIC

JUNE 14, 2024

Getty Images milla1cf Fri, 06/14/2024 - 19:30 June 14, 2024 — Until now, known risk factors for cardiac arrest have been limited to cardiovascular conditions such as hypertension and high cholesterol. million patients who sought care between 2010 and 2021 at UW Medicine, a large academic healthcare system in Seattle.

Cardiac Arrest 116

Cardiac Arrest Public Health Risk Factors Research 116

Dr. Anish Koka

JANUARY 18, 2023

The open-data movement seeks to liberate the massive amount of data generated in running clinical trials from the grasp of the academic medical-pharmaceutical industrial complex that mostly runs the most important trials responsible for bringing novel therapeutics to market. Cholesterol lowering is big business. billion dollars.

Document 52

Document Academic Heart Attack Heart attacks 52

Dr. Malcolm Kendrick

DECEMBER 31, 2022

This is a cholesterol lowering injectable drug, known as a PCSK9-Inhibitor. They all lower cholesterol (LDL) more than statins – hooray (or perhaps not). Cholesterol lowering is what the NHS now does. A place where money can be converted into both academic and medical authority. And nothing else!

Cholesterol 52

Cholesterol POTS Academic Document 52

Dr. Malcolm Kendrick

JANUARY 12, 2023

Try publishing a paper suggesting that cholesterol lowering is a waste of time, when the market for cholesterol lowering drugs is worth hundreds of billions. To quote Peter Higgs: ‘ I wouldn’t be productive enough for today’s academic system.’ Today, researchers need to be productive and drive the income stream.

Research 52

Research Cancer Innovation Academic 52